Screener
Bio-Techne TECH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | March 31, 2026 / (unaudited) | June 30, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $209,819 | $162,186 |
| Accounts receivable, less allowances of $4,415 and $4,215, respectively | 214,562 | 206,876 |
| Inventories | 201,175 | 189,446 |
| Current assets held-for-sale | — | 12,332 |
| Other current assets | 62,494 | 37,460 |
| Total current assets | 688,050 | 608,300 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's cash & equivalents?
- Bio-Techne (TECH) reported cash & equivalents of $209.82M in Q1 2026.
- How has Bio-Techne's cash & equivalents changed year-over-year?
- Bio-Techne's cash & equivalents increased by 49.2% year-over-year, from $140.67M to $209.82M.
- What is the long-term trend for Bio-Techne's cash & equivalents?
- Over 4 years (2021 to 2025), Bio-Techne's cash & equivalents has grown at a -5.0% compound annual growth rate (CAGR), from $199.09M to $162.19M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Bio-Techne's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude